<DOC>
	<DOCNO>NCT02689726</DOCNO>
	<brief_summary>A Phase 1 , Open-Label Study Evaluate Safety , Tolerability , Immunogenicity GTL001 Vaccine Adjuvanted With Imiquimod Cream HPV 16- and/or HPV 18-Infected Women Aged 25 65 Years , With Normal Cytology , ASCUS , LSIL .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity GTL001 Vaccine Adjuvanted With Imiquimod Cream HPV 16- and/or HPV 18-Infected Women Aged 25 65 Years , With Normal Cytology , ASCUS , LSIL</brief_title>
	<detailed_description>This outpatient , open-label study . After screen period 4 week , eligible subject receive 2 dos , 6 week apart , GTL001 Powder reconstitute water injection . GTL001 adjuvanted Aldara , 5 % imiquimod cream , apply injection site 15 minute 24 hour vaccination . The follow-up period 12 week first injection . The duration study define subject date sign , write informed consent provide last follow-up visit . Total duration subject participation approximately 16 week .</detailed_description>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Females age 25 65 year , inclusive , time screen . 2 . Subject generally good health base medical history clinically acceptable result , judgment investigator , follow assessment : physical examination , vital sign , clinical chemistry , hematology . 3 . Cervical HPV 16 and/or 18 infection confirm cobas® HPV Test ( Roche Molecular Systems , Inc ) realtime polymerase chain reaction ( RT PCR ) assay screen . 4 . Cervical cytological evaluation normal , ASCUS , LSIL result . 5 . Subjects childbearing potential must use effective contraception time GTL001 injection least 12 month first vaccination . Effective method birth control include result low failure rate ( ie , le 1 % per year ) use consistently correctly , implant , injectable , combined oral contraceptive , desogestrel pill , levonorgestrelreleasing intrauterine system , intrauterine device , vasectomized partner , true sexual abstinence . Subjects childbearing potential include surgically sterile postmenopausal ( menses previous 12 month ) . 6 . Subject capable understanding write informed consent , provide sign witness write informed consent , agree comply protocol requirement . 7 . In opinion investigator , subject able comply protocol high probability complete study . 1 . Current history untreated highgrade cervical lesion ( either CIN2 CIN3 ) . 2 . Current history cervical , vulvar , vaginal cancer . 3 . Prior exposure HPV prophylactic vaccine , regardless number dos receive , participation another HPV vaccination clinical trial . 4 . Current acute chronic disease , HPV 16/18 infection , would expect interfere protocoldefined evaluation . 5 . Clinically significant gynecological abnormality could interfere study procedure ( eg , prolapse , severe vaginal atrophy , myoma , hysterectomy ) judgment investigator . 6 . Malignancy , treatment malignancy , within previous 2 year , exception basal cell squamous cell carcinoma skin . 7 . Clinically important abnormality physical examination laboratory test screen period ( ie , hemoglobin level &lt; 9.5 g/dL , white blood cell &lt; 2500 cells/mm3 , aspartate aminotransferase and/or alanine aminotransferase ≥1.5 × upper limit normal [ ULN ] , creatinine ≥1.25 × ULN , alkaline phosphatase ≥2 × ULN , total bilirubin &gt; ULN ) . 8 . Administration live viral vaccine within 3 month inactivate ( nonlive ) vaccine within 2 week prior screen . 9 . Primary secondary systemic immunosuppression ( define prolong [ ≥7 day ] use corticosteroid ≥20 mg/day prednisone equivalent immunosuppressive drug ) . 10 . History severe allergy require hospital care history severe asthma require oral parenteral drug management last year . 11 . Known hypersensitivity imiquimod . 12 . History severe reaction drug vaccination . 13 . Medical condition clinical and/or biological consequence judge investigator incompatible ID vaccination . 14 . History , positive test result screen , human immunodeficiency virus , hepatitis B virus surface Ag , hepatitis C virus . 15 . Current episode symptomatic vaginal genital infection . 16 . Current episode history genital herpes . 17 . Subject pregnant lactating/breastfeeding . 18 . Use investigational drug within 30 day screen current participation another clinical trial . 19 . History recent ( within 1 year ) alcohol/drug abuse . 20 . Employee family member investigator study site personnel . 21 . Enrollment goal reach subject 's age cohort</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>